keyword
https://read.qxmd.com/read/38594380/vaccine-elicited-il-1r-signaling-results-in-th17-trm-mediated-immunity
#21
JOURNAL ARTICLE
Joseph P Hoffmann, Akhilesh Srivastava, Haoran Yang, Naoki Iwanaga, T Parks Remcho, Jenny L Hewes, Rayshma Sharoff, Kejing Song, Elizabeth B Norton, Jay K Kolls, Janet E McCombs
Lung tissue resident memory (TRM) cells are thought to play crucial roles in lung host defense. We have recently shown that immunization with the adjuvant LTA1 (derived from the A1 domain of E. coli heat labile toxin) admixed with OmpX from K. pneumoniae can elicit antigen specific lung Th17 TRM cells that provide serotype independent immunity to members of the Enterobacteriaceae family. However, the upstream requirements to generate these cells are unclear. Single-cell RNA-seq showed that vaccine-elicited Th17 TRM cells expressed high levels of IL-1R1, suggesting that IL-1 family members may be critical to generate these cells...
April 9, 2024: Communications Biology
https://read.qxmd.com/read/38591323/vaccine-adjuvants-current-status-research-and-development-licensing-and-future-opportunities
#22
REVIEW
Ying Cui, Megan Ho, Yongjie Hu, Yuan Shi
Vaccines represent one of the most significant inventions in human history and have revolutionized global health. Generally, a vaccine functions by triggering the innate immune response and stimulating antigen-presenting cells, leading to a defensive adaptive immune response against a specific pathogen's antigen. As a key element, adjuvants are chemical materials often employed as additives to increase a vaccine's efficacy and immunogenicity. For over 90 years, adjuvants have been essential components in many human vaccines, improving their efficacy by enhancing, modulating, and prolonging the immune response...
April 9, 2024: Journal of Materials Chemistry. B, Materials for Biology and Medicine
https://read.qxmd.com/read/38590674/designing-of-multi-epitope-peptide-vaccine-based-on-outer-membrane-proteins-ompf-ompc-and-pgte-of-salmonella-enterica-typhi
#23
JOURNAL ARTICLE
Ezzati Ghadi Fereshteh, Roudbari Zahra, Razavi Razieh
Consumption of contaminated water and foods by Salmonella Typhi cause the most common enteric disease known as Typhoid fever in both humans and animals. Despite the existence of various vaccines but infectious diseases remain a major cause of mortality worldwide. Nowadays, in-silico tools design a reliable and stable vaccine to combat such infections. The study aimed to design and evaluate a multi-epitope vaccine based on the outer-membrane proteins of Salmonella Typhi. B-cells and T-cells epitopes were predicted...
October 2023: Archives of Razi Institute
https://read.qxmd.com/read/38588468/multifunctional-lipidated-protein-carrier-with-a-built-in-adjuvant-as-a-universal-vaccine-platform-potently-elevates-immunogenicity-of-weak-antigens
#24
JOURNAL ARTICLE
Shi-Hao Zhou, Ru-Yan Zhang, Yu Wen, Yong-Ke Zou, Dong Ding, Miao-Miao Bian, Hong-Ying Cui, Jun Guo
Weak antigens represented by MUC1 are poorly immunogenic, which greatly constrains the development of relevant vaccines. Herein, we developed a multifunctional lipidated protein as a carrier, in which the TLR1/2 agonist Pam3 CSK4 was conjugated to the N -terminus of MUC1-loaded carrier protein BSA through pyridoxal 5'-phosphate-mediated transamination reaction. The resulting Pam3 CSK4 -BSA-MUC1 conjugate was subsequently incorporated into liposomes, which biomimics the membrane structure of tumor cells. The results indicated that this lipidated protein carrier significantly enhanced antigen uptake by APCs and obviously augmented the retention of the vaccine at the injection site...
April 8, 2024: Journal of Medicinal Chemistry
https://read.qxmd.com/read/38586014/enhanced-mucosal-b-and-t-cell-responses-against-sars-cov-2-after-heterologous-intramuscular-mrna-prime-intranasal-protein-boost-vaccination-with-a-combination-adjuvant
#25
Gabriel Laghlali, Matthew J Wiest, Dilara Karadag, Prajakta Warang, Jessica J O'Konek, Lauren A Chang, Seokchan Park, Mohammad Farazuddin, Jeffrey J Landers, Katarzyna W Janczak, Adolfo García-Sastre, James R Baker, Pamela T Wong, Michael Schotsaert
Current COVID-19 mRNA vaccines delivered intramuscularly (IM) induce effective systemic immunity, but with suboptimal immunity at mucosal sites, limiting their ability to impart sterilizing immunity. There is strong interest in rerouting immune responses induced in the periphery by parenteral vaccination to the portal entry site of respiratory viruses, such as SARS-CoV-2, by mucosal vaccination. We previously demonstrated the combination adjuvant, NE/IVT, consisting of a nanoemulsion (NE) and an RNA-based RIG-I agonist (IVT) induces potent systemic and mucosal immune responses in protein-based SARS-CoV-2 vaccines administered intranasally (IN)...
March 29, 2024: bioRxiv
https://read.qxmd.com/read/38585591/discovering-peptides-and-computational-investigations-of-a-multiepitope-vaccine-target-mycobacterium-tuberculosis
#26
JOURNAL ARTICLE
Truc Ly Nguyen, Heebal Kim
Mycobacterium tuberculosis (MTB) is the causative agent of tuberculosis (TB), a prevalent airborne infectious disease. Despite the availability of the Bacille Calmette-Guerin vaccine, its global efficacy remains modest, and tuberculosis persists as a significant global public health threat. Addressing this challenge and advancing towards the End MTB Strategy, we developed a multiepitope vaccine (MEV) based on immunoinformatics and computational approaches. Immunoinformatics screening of MBT protein identified immune-dominant epitopes based on Major Histocompatibility Complex (MHC) allele binding, immunogenicity, antigenicity, allergenicity, toxicity, and cytokine inducibility...
September 2024: Synthetic and Systems Biotechnology
https://read.qxmd.com/read/38584058/a-phase-iia-randomized-double-blind-safety-immunogenicity-and-efficacy-trial-of-plasmodium-falciparum-vaccine-antigens-merozoite-surface-protein-1-and-rts-s-formulated-with-as02-adjuvant-in-healthy-malaria-na%C3%A3-ve-adults
#27
JOURNAL ARTICLE
J F Cummings, M E Polhemus, K E Kester, C F Ockenhouse, R A Gasser, P Coyne, G Wortmann, R K Nielsen, K Schaecher, C A Holland, U Krzych, N Tornieporth, L A Soisson, E Angov, D G Heppner
BACKGROUND: To improve the efficacy of Plasmodium falciparum malaria vaccine RTS,S/AS02, we conducted a study in 2001 in healthy, malaria-naïve adults administered RTS,S/AS02 in combination with FMP1, a recombinant merozoite surface-protein-1, C-terminal 42kD fragment. METHODS: A double-blind Phase I/IIa study randomized N = 60 subjects 1:1:1:1 to one of four groups, N = 15/group, to evaluate safety, immunogenicity, and efficacy of intra-deltoid half-doses of RTS,S/AS02 and FMP1/AS02 administered in the contralateral (RTS,S + FMP1-separate) or same (RTS,S + FMP1-same) sites, or FMP1/AS02 alone (FMP1-alone), or RTS,S/AS02 alone (RTS,S-alone) on a 0-, 1-, 3-month schedule...
April 6, 2024: Vaccine
https://read.qxmd.com/read/38582693/safety-profile-of-recombinant-adjuvanted-anti-herpes-zoster-vaccine-rzv-in-high-risk-groups-data-from-active-surveillance-program-puglia-italy-2021-23
#28
JOURNAL ARTICLE
Pasquale Stefanizzi, Lorenza Moscara, Claudia Palmieri, Andrea Martinelli, Antonio Di Lorenzo, Vincenzo Venerito, Cinzia Annatea Germinario, Silvio Tafuri
BACKGROUND: Since 2021 a recombinant adjuvanted anti-Herpes Zoster vaccine(Recombinant Zoster Vaccine, RZV) is offered in Italy to high-risk patients. Few real-life data about RZV safety are available in target populations. OBJECTIVES: This study investigates Adverse Events Following Immunization(AEFIs), baseline disease flare-ups, and Herpes Zoster (HZ) episodes occurring after RZV administration in a heterogeneous population of fragile patients to design its safety profile...
April 5, 2024: Vaccine
https://read.qxmd.com/read/38580136/self-adjuvanting-polymeric-nanovaccines-enhance-ifn-production-and-cytotoxic-t-cell-response
#29
JOURNAL ARTICLE
Ming Zhao, Chunting He, Xueyun Zheng, Min Jiang, Zhiqiang Xie, Hongjiao Wei, Shujun Zhang, Ying Lin, Jiaheng Zhang, Xun Sun
Vaccines represent one of the most powerful and cost-effective innovations for controlling a wide range of infectious diseases caused by various viruses and bacteria. Unlike mRNA and DNA-based vaccines, subunit vaccines carry no risk of insertional mutagenesis and can be lyophilized for convenient transportation and long-term storage. However, existing adjuvants are often associated with toxic effect and reactogenicity, necessitating expanding the repertoire of adjuvants with better biocompatibility, for instance, designing self-adjuvating polymeric carriers...
April 3, 2024: Journal of Controlled Release
https://read.qxmd.com/read/38579013/as03-adjuvant-enhances-the-magnitude-persistence-and-clonal-breadth-of-memory-b-cell-responses-to-a-plant-based-covid-19-vaccine-in-humans
#30
JOURNAL ARTICLE
Lilit Grigoryan, Yupeng Feng, Lorenza Bellusci, Lilin Lai, Bushra Wali, Madison Ellis, Meng Yuan, Prabhu S Arunachalam, Mengyun Hu, Sangeeta Kowli, Sheena Gupta, Sofia Maysel-Auslender, Holden T Maecker, Hady Samaha, Nadine Rouphael, Ian A Wilson, Alberto C Moreno, Mehul S Suthar, Surender Khurana, Stéphane Pillet, Nathalie Charland, Brian J Ward, Bali Pulendran
Vaccine adjuvants increase the breadth of serum antibody responses, but whether this is due to the generation of antigen-specific B cell clones with distinct specificities or the maturation of memory B cell clones that produce broadly cross-reactive antibodies is unknown. Here, we longitudinally analyzed immune responses in healthy adults after two-dose vaccination with either a virus-like particle COVID-19 vaccine (CoVLP), CoVLP adjuvanted with AS03 (CoVLP+AS03), or a messenger RNA vaccination (mRNA-1273)...
April 5, 2024: Science Immunology
https://read.qxmd.com/read/38578989/multi-omics-analysis-reveals-that-linoleic-acid-metabolism-is-associated-with-variations-of-trained-immunity-induced-by-distinct-bcg-strains
#31
JOURNAL ARTICLE
Jin-Chuan Xu, Zhen-Yan Chen, Xue-Jiao Huang, Juan Wu, Huan Huang, Liang-Fei Niu, Hui-Ling Wang, Jian-Hui Li, Douglas B Lowrie, Zhidong Hu, Shui-Hua Lu, Xiao-Yong Fan
Trained immunity is one of the mechanisms by which BCG vaccination confers persistent nonspecific protection against diverse diseases. Genomic differences between the different BCG vaccine strains that are in global use could result in variable protection against tuberculosis and therapeutic effects on bladder cancer. In this study, we found that four representative BCG strains (BCG-Russia, BCG-Sweden, BCG-China, and BCG-Pasteur) covering all four genetic clusters differed in their ability to induce trained immunity and nonspecific protection...
April 5, 2024: Science Advances
https://read.qxmd.com/read/38575999/why-so-much-uncertainty-about-adjuvant-hpv-vaccines-after-local-treatment-can-the-discrepancy-between-the-positive-statistical-results-and-the-scientific-community-doubts-be-solved
#32
EDITORIAL
Paolo Giorgi-Rossi, Maria Lina Tornesello, Franco Maria Buonaguro
No abstract text is available yet for this article.
April 4, 2024: Infectious Agents and Cancer
https://read.qxmd.com/read/38575433/immunogenicity-and-safety-of-sars-cov-2-recombinant-protein-subunit-vaccine-indovac-adjuvanted-with-alum-and-cpg-1018-in-indonesian-adults-a-phase-3-randomized-active-controlled-multicenter-trial
#33
JOURNAL ARTICLE
Asrawati Nurdin, Yetty Movieta Nency, Martira Maddeppungeng, Rini Sekartini, Rini Mulia Sari, Fikrianti Surachman, Finny Fitry Yani, Raveinal, Fenty Anggrainy, Al Hafiz, Linosefa, Rizanda Machmud, Putri Awaliyah Deza, Vovinda Rujiana, Martga Bella Rahimi, Nur Farhanah, Setyo Gundi Pramudo, Rebriarina Hapsari, Dimas Tri Anantyo, Mulyono, Endang Mahati, Nani Maharani, Sidrah Darma, Andi Husni Esa Darussalam, Sharifah Shakinah, Muhammad Nasrum Massi, Soedjatmiko
BACKGROUND: Bio Farma has developed a recombinant protein subunit vaccine (IndoVac) that is indicated for active immunization in population of all ages. This article reported the results of the phase 3 immunogenicity and safety study in Indonesian adults aged 18 years and above. METHODS: We conducted a randomized, active-controlled, multicenter, prospective intervention study to evaluate the immunogenicity and safety of IndoVac in adults aged 18 years and above...
April 3, 2024: Vaccine
https://read.qxmd.com/read/38575073/the-predominant-quillaja-saponaria-fraction-qs-18-is-safe-and-effective-when-formulated-in-a-liposomal-murine-cancer-peptide-vaccine
#34
JOURNAL ARTICLE
Shiqi Zhou, Yiting Song, Anoop Nilam, Yuan Luo, Wei-Chiao Huang, Mark D Long, Jonathan F Lovell
Extracts of the Chilean soapbark tree, Quillaja Saponaria (QS) are the source of potent immune-stimulatory saponin compounds. This study compared the adjuvanticity and toxicity of QS-18 and QS-21, assessing the potential to substitute QS-18 in place of QS-21 for vaccine development. QS-18, the most abundant QS saponin fraction, has been largely overlooked due to safety concerns. We found that QS-18 spontaneously inserted into liposomes, thereby neutralizing hemolytic activity, and following administration did not induce local reactogenicity in a footpad swelling test in mice...
April 2, 2024: Journal of Controlled Release
https://read.qxmd.com/read/38573916/comparative-study-on-alginate-chitosan-microcapsules-and-montanide-isa-61-as-vaccine-adjuvants-in-mice
#35
JOURNAL ARTICLE
Laice A Silva, Monique F Souza, Thaynara P Carvalho, Clarissa H Santana, Andressa C Guedes, Jefferson Bruno S Oliveira, Pâmela A de Lima, Paulo Roberto A Nogueira, Humberto de Mello Brandão, Tatiane A da Paixão, Renato Lima Santos
Selection of adjuvant to be combined with the antigen is an extremely important point for formulating effective vaccines. The aim of this study was to evaluate reactogenicity, levels of IgM, IgG and subclasses (IgG1, IgG2b and IgG3), and protection elicited by vaccine formulations with association of chitosan coated alginate or Montanide ISA 61 with γ-irradiated Brucella ovis. The alginate/chitosan biopolymers as well as the Montanide ISA 61 emulsion elicited intense and long-lasting local response, especially when associated with the antigen...
2024: PloS One
https://read.qxmd.com/read/38572664/feasibility-of-using-a-combination-of-staphylococcal-superantigen-like-proteins-3-7-and-11-in-a-fusion-vaccine-for-staphylococcus-aureus
#36
JOURNAL ARTICLE
Janlin Ying Hui Chan, Fiona Clow, Victoria Pearson, Ries J Langley, John D Fraser, Fiona J Radcliff
Staphylococcus aureus is a significant bacterial pathogen in both community and hospital settings, and the escalation of antimicrobial-resistant strains is of immense global concern. Vaccination is an inviting long-term strategy to curb staphylococcal disease, but identification of an effective vaccine has proved to be challenging. Three well-characterized, ubiquitous, secreted immune evasion factors from the staphylococcal superantigen-like (SSL) protein family were selected for the development of a vaccine...
April 4, 2024: Immunology and Cell Biology
https://read.qxmd.com/read/38572112/ginsenoside-modified-lipid-coated-perfluorocarbon-nanodroplets-a-novel-approach-to-reduce-complement-protein-adsorption-and-prolong-in%C3%A2-vivo-circulation
#37
JOURNAL ARTICLE
Jie Zhou, Binyang Gao, Huan Zhang, Rui Yang, Jianbo Huang, Xin Li, Yi Zhong, Yan Wang, Xiaoxia Zhu, Yan Luo, Feng Yan
Lipid-coated perfluorocarbon nanodroplets (lp-NDs) hold great promise in bio-medicine as vehicles for drug delivery, molecular imaging and vaccine agents. However, their clinical utility is restricted by limited targeted accumulation, attributed to the innate immune system (IIS), which acts as the initial defense mechanism in humans. This study aimed to optimize lp-ND formulations to minimize non-specific clearance by the IIS. Ginsenosides (Gs), the principal components of Panax ginseng , possessing complement inhibition ability, structural similarity to cholesterol, and comparable fat solubility to phospholipids, were used as promising candidate IIS inhibitors...
April 2024: Acta Pharmaceutica Sinica. B
https://read.qxmd.com/read/38571947/construction-of-recombinant-pseudorabies-virus-expressing-pcv2-cap-pcv3-cap-and-il-4-investigation-of-their-biological-characteristics-and-immunogenicity
#38
JOURNAL ARTICLE
Yanting Yang, Zhiwen Xu, Qian Tao, Lei Xu, Sirui Gu, Yao Huang, Zheyan Liu, Yang Zhang, Jianhua Wen, Siyuan Lai, Ling Zhu
BACKGROUND: Porcine circovirus type 2 (PCV2) is a globally prevalent and recurrent pathogen that primarily causes slow growth and immunosuppression in pigs. Porcine circovirus type 3 (PCV3), a recently discovered virus, commonly leads to reproductive disorders in pigs and has been extensively disseminated worldwide. Infection with a single PCV subtype alone does not induce severe porcine circovirus-associated diseases (PCVD), whereas concurrent co-infection with PCV2 and PCV3 exacerbates the clinical manifestations...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38571326/the-bright-side-of-chemistry-exploring-synthetic-peptide-based-anticancer-vaccines
#39
REVIEW
Antonia D'Aniello, Alessandra Del Bene, Salvatore Mottola, Vincenzo Mazzarella, Roberto Cutolo, Erica Campagna, Salvatore Di Maro, Anna Messere
The present review focuses on synthetic peptide-based vaccine strategies in the context of anticancer intervention, paying attention to critical aspects such as peptide epitope selection, adjuvant integration, and nuanced classification of synthetic peptide cancer vaccines. Within this discussion, we delve into the diverse array of synthetic peptide-based anticancer vaccines, each derived from tumor-associated antigens (TAAs), including melanoma antigen recognized by T cells 1 (Melan-A or MART-1), mucin 1 (MUC1), human epidermal growth factor receptor 2 (HER-2), tumor protein 53 (p53), human telomerase reverse transcriptase (hTERT), survivin, folate receptor (FR), cancer-testis antigen 1 (NY-ESO-1), and prostate-specific antigen (PSA)...
April 3, 2024: Journal of Peptide Science
https://read.qxmd.com/read/38570605/immunogenicity-and-efficacy-of-vla2001-vaccine-against-sars-cov-2-infection-in-male-cynomolgus-macaques
#40
JOURNAL ARTICLE
Mathilde Galhaut, Urban Lundberg, Romain Marlin, Robert Schlegl, Stefan Seidel, Ursula Bartuschka, Jürgen Heindl-Wruss, Francis Relouzat, Sébastien Langlois, Nathalie Dereuddre-Bosquet, Julie Morin, Maxence Galpin-Lebreau, Anne-Sophie Gallouët, Wesley Gros, Thibaut Naninck, Quentin Pascal, Catherine Chapon, Karine Mouchain, Guillaume Fichet, Julien Lemaitre, Mariangela Cavarelli, Vanessa Contreras, Nicolas Legrand, Andreas Meinke, Roger Le Grand
BACKGROUND: The fight against COVID-19 requires mass vaccination strategies, and vaccines inducing durable cross-protective responses are still needed. Inactivated vaccines have proven lasting efficacy against many pathogens and good safety records. They contain multiple protein antigens that may improve response breadth and can be easily adapted every year to maintain preparedness for future seasonally emerging variants. METHODS: The vaccine dose was determined using ELISA and pseudoviral particle-based neutralization assay in the mice...
April 3, 2024: Commun Med (Lond)
keyword
keyword
32302
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.